Healthcare entity

Paysign

Company PAYS

Every one of those 1 sits in a single category, market-trends. Dyadic International is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Healthcare story that mention Paysign, all published on March 26, 2026.

Last mentioned: Mar 26, 2026

Entity pulse

Recent coverage · Paysign

1 story
6 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Paysign

Every one of those 1 sits in a single category, market-trends. Dyadic International is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Healthcare story that mention Paysign, all published on March 26, 2026. Each carries 5 original sources on average.

Stories tracked
1
Sources per story
5

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 8 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Paysign. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Paysign 2026 Outlook

    Paysign projects 30-35% revenue growth for the coming fiscal year.

  2. Recombinant Albumin Launch

    Dyadic and ProLiant initiate commercial launch of recombinant albumin.

  3. Dyadic Year-End Cash

    Dyadic ends fiscal year with $8.6 million in cash and liquid assets.

  4. Precigen Commercial Launch

    Initial commercial shipments of Papzimius for adult RRP begin.

Stories mentioning Paysign 1

Market Trends Positive

Biotech Commercialization Pivot: Dyadic and Precigen Scale Post-R&D

The Q4 2025 earnings cycle marks a critical transition for mid-cap biotech and health-IT firms as they shift from R&D-heavy profiles to commercial-stage entities. Key players like Dyadic and Precigen are reporting initial product revenues and expanded distribution networks, while service providers like Paysign see massive growth in patient affordability programs.

5 sources

Source: Motley Fool Transcribing (us) · Motley Fool Transcribing (us)

Paysign is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.